Karo Pharma AB (publ), a specialty pharma company, develops and markets prescription pharmaceuticals, over-the-counter products, medical devices, and other health related products for pharmacies and the health care sectors.
Poor track record with weak fundamentals.
Share Price & News
How has Karo Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KA6N has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: KA6N exceeded the German Pharmaceuticals industry which returned -9.1% over the past year.
Return vs Market: KA6N exceeded the German Market which returned -17.5% over the past year.
Price Volatility Vs. Market
How volatile is Karo Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Karo Pharma undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: KA6N (€4.08) is trading above our estimate of fair value (€0.07)
Significantly Below Fair Value: KA6N is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: KA6N is poor value based on its PE Ratio (909.6x) compared to the Pharmaceuticals industry average (19.6x).
PE vs Market: KA6N is poor value based on its PE Ratio (909.6x) compared to the German market (16.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KA6N's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KA6N is overvalued based on its PB Ratio (1.7x) compared to the DE Pharmaceuticals industry average (1.6x).
How is Karo Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Karo Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of KA6N’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Karo Pharma competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Karo Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KA6N has a large one-off loss of SEK107.2M impacting its December 31 2019 financial results.
Growing Profit Margin: KA6N's current net profit margins (0.5%) are lower than last year (40.7%).
Past Earnings Growth Analysis
Earnings Trend: KA6N has become profitable over the past 5 years, growing earnings by 55.2% per year.
Accelerating Growth: KA6N's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: KA6N had negative earnings growth (-98.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (1.9%).
Return on Equity
High ROE: KA6N's Return on Equity (0.2%) is considered low.
How is Karo Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: KA6N's short term assets (SEK1.2B) do not cover its short term liabilities (SEK1.5B).
Long Term Liabilities: KA6N's short term assets (SEK1.2B) do not cover its long term liabilities (SEK3.7B).
Debt to Equity History and Analysis
Debt Level: KA6N's debt to equity ratio (84.9%) is considered high.
Reducing Debt: Insufficient data to determine if KA6N's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: KA6N's debt is not well covered by operating cash flow (2.2%).
Interest Coverage: KA6N's interest payments on its debt are not well covered by EBIT (1.8x coverage).
Inventory Level: KA6N has a low level of unsold assets or inventory.
Debt Coverage by Assets: KA6N's debt is not covered by short term assets (assets are 0.2x debt).
What is Karo Pharma's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KA6N's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate KA6N's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KA6N's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KA6N's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: KA6N is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KA6N's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Christoffer Lorenzen (44yo)
Mr. Christoffer Lorenzen has been the Chief Executive Officer of Karo Pharma AB since July 1, 2019. Mr. Lorenzen was an Executive Vice President of Food Cultures & Enzymes at Chr. Hansen Holding A/S from A ...
|Chief Executive Officer||0.67yr||no data||no data|
|Chief Financial Officer||0.42yr||no data||no data|
|Vice President of Operations||0.42yr||no data||no data|
|Chief Sales Officer||0.42yr||no data||no data|
|Managing Director of Norway||no data||no data||no data|
Experienced Management: KA6N's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
|Chairman of the Board||1yr||no data||no data|
|Director||1yr||no data||no data|
|Director||1yr||no data||no data|
|Director||0.83yr||no data||no data|
|Director||0.83yr||no data||no data|
Experienced Board: KA6N's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.3%.
Karo Pharma AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Karo Pharma AB (publ)
- Ticker: KA6N
- Exchange: DB
- Founded: 1987
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr9.860b
- Listing Market Cap: kr891.663m
- Shares outstanding: 222.57m
- Website: https://www.karopharma.se
Number of Employees
- Karo Pharma AB (publ)
- Nybrokajen 7
- Stockholm County
- 111 48
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|KA6N||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Apr 1998|
|KARO||OM (OMX Nordic Exchange Stockholm)||Yes||Common Shares||SE||SEK||Apr 1998|
|0RAQ||LSE (London Stock Exchange)||Yes||Common Shares||GB||SEK||Apr 1998|
|KARB.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Apr 1998|
|KAROS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Shares||GB||SEK||Apr 1998|
Karo Pharma AB (publ), a specialty pharma company, develops and markets prescription pharmaceuticals, over-the-counter products, medical devices, and other health related products for pharmacies and the health care sectors. The company’s prescription drugs include Mollipect and TheoDur for respiratory diseases; Probecid for gout; Burinex, Centyl K, Kaleorid, Suscard, Nitroglycerin BioPhausia, and Digoxin BioPhausia for cardiovascular diseases; Laxabon and Egazil for gastro/intestinal diseases; Condyline, Synalar, Mildison, Fonx, and Conotrane for dermatology diseases; Paraflex for musculoskeletal diseases; Citodon, Morfin Special, Paralgin forte, and Trampalgin for pain; Ibux and Paracet for fever/pain; Bronkyl and Bronkyl forte for cold/flu diseases; Selexid for antibiotics; Solvezink for zinc deficiency; Lithionit for CNS/psychiatry diseases; Metformin for diabetes; and Zonat for insomnia. It also offers Allévo, a nutritional product; BabySlide, a medical device; Dosett, a solution for the storage of medicine; Mabs compression socks; and Swereco, which offers a product assortment of ergonomic products for people with disabilities. In addition, the company provides non-prescription drugs. It markets and distributes its products through retailers, pharmacies, and convenience stores in Sweden, Norway, Denmark, and Finland. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was founded in 1987 and is headquartered in Stockholm, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/31 20:52|
|End of Day Share Price||2020/03/31 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.